

# Diabetes Mellitus–Induced Microvascular Destabilization in the Myocardium



Rabea Hinkel, DVM,<sup>a,b,c</sup> Andrea Hoewe, DVM,<sup>a</sup> Simone Renner, DVM,<sup>d,e</sup> Judy Ng, PhD,<sup>a</sup> Seungmin Lee, PhD,<sup>a</sup> Katharina Klett, DVM,<sup>a,c</sup> Veronika Kaczmarek, MD,<sup>a,c</sup> Alessandra Moretti, PhD,<sup>a,b</sup> Karl-Ludwig Laugwitz, MD,<sup>a,b</sup> Philipp Skroblin, PhD,<sup>f</sup> Manuel Mayr, MD,<sup>f</sup> Hendrik Milting, MD,<sup>g</sup> Andreas Dendorfer, MD,<sup>h</sup> Bruno Reichart, MD,<sup>h</sup> Eckhard Wolf, DVM,<sup>d,e</sup> Christian Kupatt, MD<sup>a,b,h</sup>

## ABSTRACT

**BACKGROUND** Diabetes mellitus causes microcirculatory rarefaction and may impair the responsiveness of ischemic myocardium to proangiogenic factors.

**OBJECTIVES** This study sought to determine whether microvascular destabilization affects organ function and therapeutic neovascularization in diabetes mellitus.

**METHODS** The authors obtained myocardial samples from patients with end-stage heart failure at time of transplant, with or without diabetes mellitus. Diabetic (db) and wild-type (wt) pigs were used to analyze myocardial vascularization and function. Chronic ischemia was induced percutaneously (day 0) in the circumflex artery. At day 28, recombinant adeno-associated virus (rAAV) ( $5 \times 10^{12}$  viral particles encoding vascular endothelial growth factor-A [VEGF-A] or thymosin beta 4 [T $\beta$ 4]) was applied regionally. CD31+ capillaries per high power field (c/hpf) and NG2+ pericyte coverage were analyzed. Global myocardial function (ejection fraction [EF] and left ventricular end-diastolic pressure) was assessed at days 28 and 56.

**RESULTS** Diabetic human myocardial explants revealed capillary rarefaction and pericyte loss compared to nondiabetic explants. Hyperglycemia in db pigs, even without ischemia, induced capillary rarefaction in the myocardium ( $163 \pm 14$  c/hpf in db vs.  $234 \pm 8$  c/hpf in wt hearts;  $p < 0.005$ ), concomitant with a distinct loss of EF (44.9% vs. 53.4% in nondiabetic controls;  $p < 0.05$ ). Capillary density further decreased in chronic ischemic hearts, as did EF (both  $p < 0.05$ ). Treatment with rAAV.T $\beta$ 4 enhanced capillary density and maturation in db hearts less efficiently than in wt hearts, similar to collateral growth. rAAV.VEGF-A, though stimulating angiogenesis, induced neither pericyte recruitment nor collateral growth. As a result, rAAV.T $\beta$ 4 but not rAAV.VEGF-A improved EF in db hearts ( $34.5 \pm 1.4\%$ ), but less so than in wt hearts ( $44.8 \pm 1.5\%$ ).

**CONCLUSIONS** Diabetes mellitus destabilized microvascular vessels of the heart, affecting the amplitude of therapeutic neovascularization via rAAV.T $\beta$ 4 in a translational large animal model of hibernating myocardium. (J Am Coll Cardiol 2017;69:131–43) © 2017 by the American College of Cardiology Foundation.

Diabetes mellitus (DM) is one of the most important risk factors for developing cardiovascular disease (1,2). Moreover, DM induces additional major adverse coronary events after percutaneous coronary interventions (3–6) and bypass grafting, particularly if poorly controlled (7). This comparative disadvantage is also evident when interventions are performed for acute coronary



Listen to this manuscript's audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.



From the <sup>a</sup>I. Medizinische Klinik und Poliklinik, University Clinic Rechts der Isar, Technical University of Munich, Munich, Germany; <sup>b</sup>DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany; <sup>c</sup>Institute for Cardiovascular Prevention, Klinikum der Universität München, Munich, Germany; <sup>d</sup>Gene Center and Department of Veterinary Sciences, Ludwig Maximilian University of Munich, Munich, Germany; <sup>e</sup>German Center for Diabetes Research (DZD), Neuherberg, Germany; <sup>f</sup>King's College London British Heart Foundation Centre, London, United Kingdom; <sup>g</sup>Erich & Hanna Klessmann Institute, Heart and Diabetes Center North Rhine-Westphalia, Bad Oeynhausen, Germany; and the <sup>h</sup>Walter-Brendel-Centre for Experimental Medicine, Ludwig Maximilian University of Munich, Munich, Germany. This work was funded by the German Research Foundation (DFG, TRR 127 to Drs. Hinkel, Reichart, Wolf, and Kupatt), the German Center for Cardiovascular Research (DZHK), the German Center for Diabetes Research (DZD), and the German Ministry for Education and Research (BMBF 01GU1105 to Dr. Kupatt). Dr. Mayr has filed and licensed patent applications on microRNA biomarkers. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Manuscript received July 27, 2016; revised manuscript received October 10, 2016, accepted October 12, 2016.

## ABBREVIATIONS AND ACRONYMS

**Ang** = angiotensin  
**c/hpf** = capillaries per high power field  
**db** = diabetic  
**LV** = left ventricular  
**miR** = microRNA  
**p/hpf** = pericytes per high power field  
**rAAV** = recombinant adeno-associated virus  
**RCx** = ramus circumflex  
**Tβ4** = thymosin beta 4  
**VEGF-A** = vascular endothelial growth factor A  
**wt** = wild type

syndromes (8) and for chronic coronary lesions, aimed at resolving contractile dysfunction in viable myocardium (i.e., hibernating myocardium) (9,10).

Apparently, macrovascular treatment options for coronary obstructions are antagonized by additional factors beyond the reach of conventional recanalization strategies (11). A continuous inflammatory disposition of microvessels has been attributed to vessel regression in most organs (12), except for reactive inflammatory vessel growth in the eye (13). Both rarefaction and capillary sprouting imply vessel destabilization as a common denominator. In this concept, pericyte detachment is caused by inflammatory endothelial activation (13). The diabetic inflammatory process might be aggravated by

exogenous vessel-destabilizing factors such as vascular endothelial growth factor A (VEGF-A) (14), potentially blunting its efficacy in therapeutic neovascularization. Enhancing microvascular stability (e.g., by providing platelet-derived growth factor B for pericyte attraction) has been demonstrated to increase blood flow into ischemic myocardium, when added to VEGF-A (15). One vascular growth factor,

SEE PAGE 144

which provides both capillary sprouting and pericyte investment, is thymosin beta 4 (Tβ4) (16), which induces lasting and functional microvascular networks in wild-type (wt) animals, and stabilizes microvessels in the instance of inflammation (17).

To determine whether microvascular destabilization affects organ function and therapeutic neovascularization in a clinically relevant large animal model, we studied ischemic cardiomyopathy in *INS<sup>C94Y</sup>* transgenic pigs, a model of permanent neonatal DM (18). In this model, fasting glucose levels increased to 300 to 400 mg/dl after birth. We analyzed hearts of 5-month-old db and wt pig hearts with or without hibernating myocardium, and applied regional adeno-associated virus (AAV)-based vascular gene therapy in the latter. Our results indicated that molecular treatment aiming at balanced vascular growth and maturation can improve hibernating myocardium in individuals with DM, although to a lesser extent than in age-matched non-DM controls.

## METHODS

Tissue samples of the nonischemic and ischemic animals (ramus circumflex [RCx] perfused area, wt and db) and patient samples (5 in the non-DM and 4 in the

DM group, left ventricle [LV], ischemic area) were analyzed for capillary density (platelet endothelial cell adhesion molecule-1-positive cells) and pericyte investment (NG2-positive cells). More information about tissue staining is in the [Online Appendix](#).

Myocardial tissue specimens were procured from patients undergoing heart transplantation ([Online Table 1](#)). Patients provided informed consent for the scientific use of the explanted tissue. The study was approved by the institutional ethics boards of the clinical and experimental study contributors (H.M., A.D.). Specimens of LV myocardium (4 in the non-DM and 5 in the DM group) were obtained as 2 × 2 cm<sup>2</sup> transmural biopsies from explanted failing hearts at the Heart and Diabetes Center of North Rhine-Westphalia, and were prepared as described in the [Online Appendix](#).


Isometric contraction force was measured at a preload of 1 mN under continuous field stimulation (rate 0.5 Hz, pulse duration 3 ms) at 1.5-fold excitation threshold. Strain- and rate-related alterations of contractility were determined in the presence of 1 μM isoprenaline. Maximum twitch force was assessed at optimum preload. Tissue elastance was calculated from the increase in diastolic tension provoked by a 1 mm extension beyond relaxed length.

The preparation of cells for direct Matrigel assays (BD Biosciences, Heidelberg, Germany), pericyte coculture experiments, and shear stress experiments is described in the [Online Appendix](#).

Recombinant AAV (rAAV) 2.9 vectors encoding β-galactosidase lacZ, Tβ4, or VEGF-A were produced using the triple transfection method as described earlier (19) and in the [Online Appendix](#).

Transgenic pigs presenting with permanent neonatal DM were generated as described previously (18). The *INS<sup>C94Y</sup>* mutation disrupts 1 of the 2 disulfide bonds between the A and B chains of the insulin molecule, resulting in misfolded insulin, impaired insulin secretion, endoplasmic reticulum stress, and apoptosis of the pancreatic beta cells. Consequently, these transgenic pigs present with permanent neonatal DM, which was treated with insulin until 7 days before experiment onset. Healthy nontransgenic littermates served as controls ([Online Figure 1A](#)).

German landrace pigs were anesthetized and instrumented as previously described (20) and in the [Online Appendix](#). Of 37 animals initiated by stent placement, 5 (3 wt and 2 db) were lost due to sudden cardiac death during the first 28 days, whereas no animal was lost between days 28 and 56. The remaining 32 animals (14 wt, 18 db) were treated by mock transduction (5 × 10<sup>12</sup> rAAV containing no transgene; n = 7 wt, n = 6 db), rAAV.VEGF-A transduction (5 × 10<sup>12</sup> particles;




n = 5 db), or rAAV.T $\beta$ 4 transduction ( $5 \times 10^{12}$  particles; n = 7 wt and db) via continuous pressure-regulated retroinfusion into the lateral vein (20).

Twenty-eight days after implantation of a reduction stent, the myocardium was transduced with T $\beta$ 4 or VEGF-A by selective pressure regulated retroinfusion


of  $5 \times 10^{12}$  rAAV.T $\beta$ 4 or  $1 \times 10^{13}$  rAAV.VEGF-A particles into the lateral vein, which anatomically drains the RCx-perfused myocardium (15) (Online Figure 1B). Four weeks later (day 56), we assessed collateral morphology and myocardial function as well as performed tissue harvesting for histochemical analysis.

**FIGURE 2 High Glucose Levels Alter Proangiogenic Effects**



**(A)** Tube formation capacity of murine endothelial cells is altered under high glucose levels; Tβ4 and vascular endothelial growth factor-A (VEGF-A) transfection enhanced tube formation under normal and high glucose levels (scale bar = 200 μm). **(B)** Similarly, high glucose reduced endothelial cell migration in vitro in a wound-scratch assay (red area = uncovered area; scale bar = 200 μm) whereas Tβ4 or VEGF-A overexpression enhanced migration capacity in normal- and high-glucose conditions. **(C and D)** High glucose levels reduced tube maturation, assessed as pericyte recruitment (green fluorescence) to endothelial rings (red fluorescence; scale bar = 100 μm); transfection of Tβ4, but not of VEGF-A, enhanced maturation at normal and high glucose levels. **(E)** High glucose levels increased adhesion of human monocytic THP-1 cells under venular shear stress (4 dyn/s; scale bar = 100 μm); Tβ4 transfection reduced this endothelium-leukocyte interaction in normal and high glucose levels. Mean ± SEM; n = 3. \*p < 0.05; \*\*p < 0.001. Abbreviations as in Figure 1.

**FIGURE 3 Capillary Rarefaction**




**(A)** Fasted blood glucose levels are enhanced in the transgenic diabetic (db) pigs (C94Y mutation in the porcine insulin gene) compared to the wild-type (wt) littermates. In cardiac tissue, **(B and C)** capillary density (PECAM-1+) and **(B and D)** vessel integrity (NG2+) were reduced in the transgenic db versus wt pigs. **(E and F)** Fibrosis (scale bar = 100  $\mu$ m) was significantly increased in db hearts. Transgenic db pigs also demonstrated **(G)** reduced ejection fraction (EF) and **(H)** diminished contractile functional reserve assessed by subendothelial sonomicrometry at rest and rapid atrial pacing (120 and 150 beats/min [bpm]). **(I)** Left ventricular end-diastolic pressure (LVEDP) increased under high-glucose conditions in db pigs. Mean  $\pm$  SEM; n = 4. \*p < 0.05; \*\*p < 0.001. SES = subendocardial segment shortening; other abbreviations as in **Figures 1 and 2**.

Global myocardial function was assessed at days 28 and 56 by means of a pressure-tip catheter placed in the left ventricle (for LV end-diastolic and systolic pressures,  $dP/dt_{max}$  [contraction velocity], and

$dP/dt_{min}$  [relaxation velocity]), whereas LV angiography was performed in anterior-posterior position for the analysis of ejection fraction, yielding slightly smaller control values than a right anterior oblique

**FIGURE 4 DM Relevance for Vascularization in Chronic Myocardial Ischemia**





view. At day 56, subendocardial segment shortening was performed after placing sonomicrometry crystal pairs into the ischemic (circumflex-perfused) region and normalized to measurements in the control region (left anterior descending artery perfused area). Though 1 animal of the treatment group died during subendocardial segment shortening assessment, it provided all other data.

Post-mortem angiograms were taken for visualization of collateral formation and Rentrop score analysis: 0 = no filling; 1 = side branch filling; 2 = partial main vessel filling; and 3 = complete main vessel filling. Tissue from nonischemic and ischemic LV myocardium was utilized for determining capillary density.

**STATISTICAL METHODS.** The results are given as mean  $\pm$  SEM. Statistical analysis of results between more than 2 experimental groups was performed with 1-way analysis of variance; 2-way analysis of variance was applied in all other figures that compared more than 2 groups and more than 1 condition. Whenever a significant effect was obtained with analysis of variance, we performed multiple comparison tests between the groups using the Student Newman-Keuls procedure. Two experimental groups were compared by Student *t* test. All procedures were performed with an SPSS Version 19.0.2 (IBM Corporation, Armonk, New York). Differences between groups were considered significant at  $p < 0.05$ .

## RESULTS

Although db microvascular alterations are well known in peripheral or retinal tissue of patients, data are scarce that describe a structure-function correlation in db hearts. Therefore, we first compared myocardium of end-stage hearts from patients with and without DM undergoing heart transplantation, utilizing specimens of freshly explanted hearts for histological and functional analyses. We found a distinct capillary rarefaction and pericyte loss in hearts derived from patients with DM (Figures 1A to 1C), accompanied by a lowered angiopoietin (Ang) 1/Ang2 ratio in the DM group (Figure 1D). This microvascular alteration coin-

cided with a loss of contractility in the papillary muscle ex vivo (Figure 1E). Moreover, wall stiffness, a parameter for impaired ventricular filling indicating diastolic heart failure, was found increased in the same hearts (Figure 1F), all confirming a correlation between microvascular disturbance and dysfunction in hearts from DM patients.

Next, we investigated the impact of increased glucose levels on sprouting and maturation of endothelial cells in vitro. We used 2 well-known proangiogenic stimuli, VEGF-A and T $\beta$ 4 (16), to induce tube formation of microvascular endothelial cells (bEnd3 and human umbilical venous endothelial cells). Under normal glucose conditions, cells displayed a high spontaneous tube formation rate, which was almost 2-fold increased upon T $\beta$ 4 stimulation (Figure 2A). Tube formation was reduced at high glucose concentration (61% of cells at normal glucose), but increased to 174% upon T $\beta$ 4 and 162% upon VEGF-A stimulation (Figure 2A). Consistently, T $\beta$ 4 enhanced the migratory capacity of endothelial cells in vitro in both normo- and high-glucose conditions, although to a lesser extent in the high-glucose culture condition (Figure 2B). Of note, although T $\beta$ 4 increased pericyte recruitment to the newly formed capillary rings at normo- and high-glucose conditions, adding VEGF-A did not alter pericyte recruitment and high-glucose conditions impaired the capability of endothelial cells to attract pericytic cells to newly formed capillary rings (Figures 2C and 2D).


The proangiogenic endothelial activation of T $\beta$ 4 under normo- and high-glucose conditions did not induce proinflammatory events, because adhesion of monocytic THP-1 cells to endothelial cells decreased in both conditions upon T $\beta$ 4 treatment (Figure 2E). Nevertheless, adhesion of THP-1 cells on endothelial cells was found increased at high compared to normal glucose levels, pointing to a chronic inflammatory state of db endothelium (Figure 2E).

Next, we investigated the impact of high glucose levels on the microcirculatory status and myocardial function in otherwise unchallenged hearts in vivo. Noteworthy, at 5 months of age with blood glucose levels  $>300$  mg/dl (Figure 3A), a distinct capillary

### FIGURE 4 Continued


(A) Fasted blood glucose levels are enhanced in db pigs at days 0, 28, and 56 versus their age-matched wt littermates. Chronic myocardial ischemia leads to (B and C) capillary rarefaction (PECAM-1+) in both wt and db pig hearts. The reduced capillary number is associated with (B and D) a loss of pericytes (NG2+) in the ischemic tissue in both control groups. This effect was at least partially reversed after rAAV.T $\beta$ 4 transduction, less so in db animals, an effect not observed after rAAV.VEGF-A application. (E) Representative pictures and (F) quantification of collateral growth, measured at day 56, which was enhanced after rAAV.T $\beta$ 4 application; rAAV.VEGF-A application showed no cardioprotective effect. (G) Perfusion of the vessel distal to the occlusion site, displayed as Rentrop score, revealed a reduced filling in wt and db control animals. T $\beta$ 4, but not VEGF-A overexpression, was capable of enhancing vessel perfusion. Mean  $\pm$  SEM; n = 6 to 8. \* $p < 0.05$ ; \*\* $p < 0.001$ . rAAV = recombinant adeno-associated virus; other abbreviations as in Figures 1 to 3.

**FIGURE 5** T $\beta$ 4-Induced Cardioprotection



**(A)** Systolic myocardial function, measured by EF, improved in rAAV.T $\beta$ 4-transduced but not in rAAV.VEGF-A treated animals at day 56. **(B)** Change from day 28 to 56 ( $\Delta$ EF) showed comparable changes in wt and db rAAV.T $\beta$ 4 animals, although at different levels. **(C)** LVEDP increased in wt and db ischemic hearts days 28 to 56, unless T $\beta$ 4 was overexpressed. VEGF-A transduction did not reduce the enhanced LVEDP in the ischemic db hearts. **(D)** Change from days 28 to 56 ( $\Delta$ LVEDP) showed similar effects in wt and db rAAV.T $\beta$ 4 animals, but at different levels. **(E)** Functional reserve in the nonischemic (left anterior descending region) tissue is diminished in db hearts compared to normoglycemic animals. **(F)** In the ischemic (ramus circumflexus region), rAAV.T $\beta$ 4 application enhanced myocardial contractile function in both wt and db animals, whereas rAAV.VEGF-A showed no protective effect. Mean  $\pm$  SEM; n = 6 to 8. \*p < 0.05; \*\* p < 0.001. Abbreviations as in Figures 1 to 4.





rarefaction was detectable in normoxic db pig hearts ( $163 \pm 14$  capillaries per high power field [c/hpf] in db vs.  $234 \pm 8$  c/hpf in wt) (Figures 3B and 3C). Moreover, pericyte investment of the remaining capillaries was decreased, rendering the microcirculatory networks in nonischemic hearts impaired ( $144 \pm 6$  vs.  $219 \pm 4$  pericytes per hpf [p/hpf]) (Figures 3B and 3D). Coincidentally, an increase in interstitial fibrosis was noted in db hearts ( $15.6 \pm 0.6\%$  vs.  $2.1 \pm 0.5\%$ ) (Figures 3E and 3F). This structural alteration was associated with an impairment of systolic parameters such as ejection fraction ( $44.9 \pm 1.9\%$  in db vs.  $53.4 \pm 1.2\%$  in wt hearts) (Figure 3G). Consistently, db hearts demonstrated a decrease in functional reserve

( $6.6 \pm 1.3\%$  vs.  $15.4 \pm 2.3\%$  at 150 beats/min) (Figure 3H) as well as an increase of LV end-diastolic pressure ( $12.7 \pm 1.0$  mm Hg vs.  $8.2 \pm 0.7$  mm Hg) (Figure 3I).

In a second set of experiments, we analyzed the response of db porcine hearts (blood glucose >300 mg/dl) (Figure 4A) and age-matched control hearts subjected to regional chronic ischemia inflicted by gradual occlusion of the circumflex artery. We found a higher degree of microcirculatory rarefaction in db than in normoglycemic hibernating myocardium ( $129 \pm 7$  c/hpf vs.  $150 \pm 4$  c/hpf) (Figures 4B and 4C). Pericyte investment of capillaries was also decreased in db hearts ( $106 \pm 4$  p/hpf vs.  $136 \pm 5$  p/hpf)

(Figures 4B to 4D). Of note, rAAV.T $\beta$ 4 transduction significantly induced capillary growth and maturation in db pigs ( $183 \pm 9$  c/hpf,  $163 \pm 14$  p/hpf), although it was less pronounced than in wt hearts ( $294 \pm 6$  c/hpf,  $286 \pm 7$  p/hpf) (Figures 4B to 4D). Treatment of db hearts with rAAV.VEGF-A treatment yielded an increase in capillaries ( $192 \pm 4$  c/hpf) (Figures 4B and 4C). However, the pericyte investment did not concomitantly increase ( $87 \pm 4$  p/hpf) (Figures 4B and 4D).

The number of collaterals, which may be formed to compensate for chronic total RCx occlusion, was low in both db and wt groups ( $2.1 \pm 0.5$  visible collaterals per heart vs.  $1.9 \pm 0.2$  visible collaterals per heart) (Figures 4E and 4F). Upon rAAV.T $\beta$ 4 transduction, however, collateral formation increased to a larger extent in wt hearts ( $6.7 \pm 0.5$  collaterals/heart) than in db hearts ( $4.7 \pm 0.3$  collaterals/heart) (Figures 4E and 4F). Consistently, Rentrop score indicating distal filling of the occluded vessel reached a higher level in wt hearts than in db hearts ( $2.6 \pm 0.2$  vs.  $2.1 \pm 0.1$ ) (Figures 4E and 4G). Notably, rAAV.VEGF-A treatment did not increase arteriogenesis in the ischemic region of db hearts ( $2.2$  collaterals/heart), with a Rentrop score at control level (rAAV.VEGF-A  $1.2 \pm 0.2$  vs. control  $1.4 \pm 0.2$ ) (Figures 4E to 4G).

The structural impairment of db microvasculature blunted the functional response of therapeutic neovascularization: the gain of ejection fraction induced by rAAV.T $\beta$ 4 treatment was less pronounced in the db compared to the wt group (Figures 5A and 5B, Online Figure 2A). Consistently, the rise in LV end-diastolic pressure observed in untreated ischemic animals (Figure 5C, Online Figure 2B) was reversed after rAAV.T $\beta$ 4 treatment in either background (Figures 5C and 5D). Moreover, the level of regional myocardial function in the nonischemic area under rapid pacing was significantly reduced in db hearts (db  $8.8 \pm 1.2\%$  vs. wt  $16.7 \pm 1.0\%$ ) (Figure 5E). In the ischemic region, recovery upon rAAV.T $\beta$ 4 treatment was present in db hearts ( $8.5 \pm 1.4\%$  in treated db hearts vs.  $1.9 \pm 0.8\%$  in untreated db hearts), but significantly less pronounced than in wt hearts (rAAV.T $\beta$ 4  $16.0 \pm 1.2\%$ ) (Figure 5F). In the ischemic region of db hearts, rAAV.VEGF-A did not alter functional reserve ( $2.9 \pm 0.7\%$ ) (Online Figure 2C).

Because the complex myovascular interaction in db hearts destabilized microvessels and inhibited therapeutic vessel growth, we investigated the Ang1/Ang2 ratio in the ischemic hearts. The reduced Ang1/Ang2 ratio in ischemic tissue was enhanced upon T $\beta$ 4 overexpression in wt as well as db hearts (Figure 6A, Online Figure 1C). However, rAAV.VEGF-A application did not


improve the Ang1/Ang2 ratio, pointing to the lack of mature microvascular growth. In addition, we investigated the alterations in microribonucleic acid (miR), which might account for the pleiotropic actions induced by the hyperglycemic state. Three vasoactive miRs were found up-regulated in the hyperglycemic hearts (Online Figure 3): miR 26a, which is implicated in impaired wound healing angiogenesis in DM (21); miR 92a, a known inhibitor of cardiac angiogenesis (22,23); and miR 133a, whose level was previously reported to be elevated in db hearts (24). We found these 3 miRs significantly up-regulated in the porcine db hearts (Online Figure 3), suggesting them as potential novel mediators of microvascular rarefaction in DM. Furthermore, fibrosis was induced in the ischemic tissue (db  $22.5 \pm 1.0\%$  vs. wt  $19.0 \pm 0.8\%$ ) (Figures 6B and 6C). rAAV.T $\beta$ 4 application significantly reduced fibrosis in db as well as wt hearts ( $13.1 \pm 0.6\%$  and  $11.0 \pm 0.4\%$ , respectively) (Figures 6B and 6C).

## DISCUSSION


In the current study, we assessed the impact of cardiovascular risk factors on the induction of vascular growth in the microvascular and macrovascular compartment. We found that db human hearts displayed capillary rarefaction and pericyte loss, accompanied by decreased contractility and increased stiffness (Figure 1). Moreover, hyperglycemia attenuated tube formation, migration, and pericyte attraction upon proangiogenic stimulation in vitro (Figure 2). In vivo, untreated DM induced microcirculatory rarefaction (Figure 3) and a distinct functional cardiac impairment in a transgenic *INS*<sup>C94Y</sup> pig model. Induction of regional chronic ischemia impaired microvascular density in both hyperglycemic and normoglycemic hearts, without functional collateralization of the ischemic region (Figure 4). Forced angiogenesis via rAAV.VEGF-A, without concomitant vessel maturation had no significant effect on regional and global function at rest and under rapid pacing (Figures 4 and 5). However, balanced vascular growth was induced via rAAV.T $\beta$ 4 in db pig hearts, though to a significantly lesser extent than in wt hearts (Figure 4). Functional impairment of hibernating myocardium was improved in db hearts upon T $\beta$ 4 treatment, albeit not to the same extent as in normoglycemic hearts (Figure 5). MiR analysis of db hearts revealed increased concentrations of anti-angiogenic miR 26a, miR 92a, and miR 133a. Additionally, a higher degree of fibrosis was observed, which was partially reversed by T $\beta$ 4 and VEGF-A (Figure 6, Online Figure 3). The Central Illustration

**CENTRAL ILLUSTRATION** T $\beta$ 4 Gene Therapy and Therapeutic Neovascularization


Wild-type Normoxia




Diabetes mellitus Ischemia



Diabetes mellitus Ischemia + rAAV.T $\beta$ 4



Diabetes mellitus Ischemia + rAAV.VEGF-A



Hinkel, R. et al. *J Am Coll Cardiol.* 2017;69(2):131-43.

Diabetes mellitus impairs vascular density in the heart. Proangiogenic gene therapy via thymosin beta 4 (T $\beta$ 4) or vascular endothelial growth factor-A (VEGF-A) induces capillary growth in the diabetic heart. However, only T $\beta$ 4 is capable of inducing therapeutic neovascularization via vessel growth and maturation, thereby improving perfusion and myocardial function in ischemic normal as well as diabetic hearts. rAAV = recombinant adeno-associated virus.

depicts the specific microcirculatory alterations of DM and the effects of T $\beta$ 4 and VEGF-A.

Notably, uncontrolled diabetes with continuously elevated glucose levels (Figure 3A) itself suffices to rarefy microcirculatory density of cardiac muscle. Capillary loss and pericyte dropout have been well described in the retina (25), but are revealed for the first time in transgenic db pig hearts and in hearts

from patients with diabetes. Previously, microvessel destabilization has been attributed to Ang2 overexpression (26). A partial inhibitor of the tyrosine kinase with immunoglobulin-like and EGF-like domains 2 (Tie2) receptor, Ang2 might destabilize microvessels by antagonizing the Ang1/Tie2 interaction, which provides a quiescent and mature vessel state. This feature has been attributed to

inflammatory destabilization of microvessels in sepsis (27), but may also occur in chronic inflammatory endothelial activation (25) or in streptozotocin-induced experimental DM (28). Notably, increased Ang2 expression has been found in aged db/db mice characterized by capillary rarefaction and fibrosis (29). In our study, the ratio of Ang1/Ang2 was slightly, but not significantly, decreased in db pig and human hearts compared to normoglycemic hearts (Figures 1D and 6A, Online Figure 1C), but increased upon rAAV.T $\beta$ 4 treatment. In the human tissue, T $\beta$ 4 expression was unaltered even though DM human corneas display a distinct T $\beta$ 4 reduction (30). However, the vascular growth induction by T $\beta$ 4 was previously found to be sensitive to Ang2 (16). Thus, an improved Ang1/Ang2 ratio appears crucial for the balanced vascular growth provided by rAAV.T $\beta$ 4.

Interestingly, rAAV.VEGF-A had no effect on the Ang1/Ang2 ratio (Figure 6A, Online Figure 1C). This was consistent with our previous observation in normoglycemic chronic ischemic pig hearts (15), where rAAV.VEGF-A did not yield sufficient microvessel maturation nor macrovessel growth (arteriogenesis) for functional improvement in our hibernating myocardium model. Lack of microvessel maturation was found critical, because addition of placenta-derived growth factor B to VEGF-A sufficed to induce augmentation of micro- and macrovessels as well as functional improvement (15).

With rAAV.T $\beta$ 4 treatment, we found a decrease of CD14<sup>+</sup> monocytes, representing the proinflammatory M1 phenotype, in normoglycemic and hyperglycemic pig hearts (Online Figure 1D). One potential signal triggering continuous inflammation is increased binding of advanced glycation endproducts to their receptor (14). Besides its intracellular proinflammatory signaling and high mobility group box 1- and nuclear factor  $\kappa$ B-dependent up-regulation of adhesion molecules (31), cytokines, and chemokines, advanced glycation endproducts to their receptor itself interact with Mac-1 on circulating leukocytes, mediating firm adhesion (32,33) and further inflammatory stimulation. Moreover, in metabolic stress (e.g., DM) endosomal damage-associated molecular patterns may activate the inflammasome for a perpetual inflammatory state (34). Finally, miR alterations may take a toll of microvascular preservation. In this respect, miR 92a, miR 26a, and miR133b have shown a distinct increase in hyperglycemia (Online Figure 3), which may indicate their involvement in db vascular rarefaction and suggest them as potential therapeutic targets for miR inhibitors (23).

**STUDY LIMITATIONS.** In this study, we used a transgenic pig model of insulin-dependent DM to investigate the efficacy of vascular gene therapy using rAAV.T $\beta$ 4 and rAAV.VEGF-A as therapeutic agents. Thus, we analyzed an untreated cardiac risk factor, representing a worst-case scenario for a potential loss of treatment function. We assume that most patients of the target population receive current medical treatment schemes, blunting the described loss of efficacy. Nevertheless, comorbidities such as DM must be taken into account when calculating the size of a potential treatment effect.

## CONCLUSIONS

We used a transgenic db pig model to quantify vessel growth and functional improvement in hibernating myocardium subjected to rAAV.T $\beta$ 4 therapy to improve neovascularization. Our results indicated an attenuated, but still significant, increase of microvessels and macrovessels that improved myocardial function. Thus, we concluded that in the presence of DM, balanced vascular gene therapy, targeting microvascular maturation, and macrovascular growth in addition to angiogenesis is effective, although not to the same extent as in healthy wt animals.

**ACKNOWLEDGMENT** The authors thank Anja Wolf for expert technical assistance.

**REPRINT REQUESTS AND CORRESPONDENCE:** Dr. Christian Kupatt, 1. Med. Klinik, University Clinic Rechts der Isar, Technical University Munich, Ismaninger Strasse 22, 81675 Munich, Germany. E-mail: christian.kupatt@tum.de.

## PERSPECTIVES

**COMPETENCY IN MEDICAL KNOWLEDGE:** In a transgenic, porcine model of DM (InsC94Y), microcirculatory instability compromises myocardial function and angiogenesis.

**TRANSLATIONAL OUTLOOK:** Future researchers should seek ways to promote capillary stability in patients with diabetes, as this may help preserve myocardial function and reduce myocardial ischemia.

## REFERENCES

1. Kannel WB. The Framingham Study: ITS 50-year legacy and future promise. *J Atheroscler Thromb* 2000;6:60-6.
2. Kim J-J, Hwang B-H, Choi IJ, et al. Impact of diabetes duration on the extent and severity of coronary atheroma burden and long-term clinical outcome in asymptomatic type 2 diabetic patients: evaluation by coronary CT angiography. *Eur Heart J Cardiovasc Imaging* 2015;16:1065-73.
3. Bittner V, Bertollet M, Barraza FR, et al. Comprehensive cardiovascular risk factor control improves survival: the BARI 2D trial. *J Am Coll Cardiol* 2015;66:765-73.
4. Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL. Troponin and cardiac events in stable ischemic heart disease and diabetes. *N Engl J Med* 2015;373:610-20.
5. Baber U, Mehran R, Giustino G, et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. *J Am Coll Cardiol* 2016;67:2224-34.
6. Schoos MM, Dangas GD, Mehran R, et al. Impact of hemoglobin A1c levels on residual platelet reactivity and outcomes after insertion of coronary drug-eluting stents (from the ADAPT-DES Study). *Am J Cardiol* 2016;117:192-200.
7. Nyström T, Holzmann MJ, Eliasson B, Kuhl J, Sartipy U. Glycemic control in type 1 diabetes and long-term risk of cardiovascular events or death after coronary artery bypass grafting. *J Am Coll Cardiol* 2015;66:535-43.
8. Klempfner R, Elis A, Matezky S, et al. Temporal trends in management and outcome of diabetic and non-diabetic patients with acute coronary syndrome (ACS): residual risk of long-term mortality persists: Insights from the ACS Israeli Survey (ACSIS) 2000-2010. *Int J Cardiol* 2015;179:546-51.
9. Schuster A, Morton G, Chiribiri A, Perera D, Vanoverschelde JL, Nagel E. Imaging in the management of ischemic cardiomyopathy: special focus on magnetic resonance. *J Am Coll Cardiol* 2012;59:359-70.
10. BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. *J Am Coll Cardiol* 2007;49:1600-6.
11. Rosenson RS, Fioretto P, Dodson PM. Does microvascular disease predict macrovascular events in type 2 diabetes? *Atherosclerosis* 2011;218:13-8.
12. Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. *J Am Coll Cardiol* 2009;53:535-42.
13. Hammes H-P, Feng Y, Pfister F, Brownlee M. Diabetic retinopathy: targeting vasoregression. *Diabetes* 2011;60:9-16.
14. Shoji T, Koyama H, Morioka T, et al. Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. *Diabetes* 2006;55:2245-55.
15. Kupatt C, Hinkel R, Pfosser A, et al. Cotransfection of vascular endothelial growth factor-A and platelet-derived growth factor-B via recombinant adeno-associated virus resolves chronic ischemic malperfusion: role of vessel maturation. *J Am Coll Cardiol* 2010;56:414-22.
16. Hinkel R, Trenkwalder T, Petersen B, et al. MRTF-A controls vessel growth and maturation by increasing the expression of CCN1 and CCN2. *Nat Commun* 2014;5:3970.
17. Bongiovanni D, Ziegler T, D'Almeida S, et al. Thymosin beta4 attenuates microcirculatory and hemodynamic destabilization in sepsis. *Expert Opin Biol Ther* 2015;15 Suppl 1:S203-10.
18. Renner S, Braun-Reichhart C, Blutke A, et al. Permanent neonatal diabetes in INSC94Y transgenic pigs. *Diabetes* 2013;62:1505-11.
19. Bish LT, Morine K, Sleeper MM, et al. AAV9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. *Hum Gene Ther* 2008;19:1359-68.
20. Kupatt C, Hinkel R, von Bruhl ML, et al. Endothelial nitric oxide synthase overexpression provides a functionally relevant angiogenic switch in hibernating pig myocardium. *J Am Coll Cardiol* 2007;49:1575-84.
21. Icli B, Nabzdyk CS, Lujan-Hernandez J, et al. Regulation of impaired angiogenesis in diabetic dermal wound healing by microRNA-26a. *J Mol Cell Cardiol* 2016;91:151-9.
22. Bonauer A, Carmona G, Iwasaki M, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. *Science* 2009;324:1710-3.
23. Hinkel R, Penzkofer D, Zuehlke S, et al. Inhibition of microRNA-92a protects against ischemia-reperfusion injury in a large animal model. *Circulation* 2013;128:1066-75.
24. Fichtlscherer S, Zeiher AM, Dimmeler S. Circulating microRNAs: biomarkers or mediators of cardiovascular diseases? *Arterioscler Thromb Vasc Biol* 2011;31:2383-90.
25. Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. *Nat Med* 2003;9:294-9.
26. Hammes HP, Lin J, Wagner P, et al. Angiotensin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. *Diabetes* 2004;53:1104-10.
27. Ziegler T, Horstkotte J, Schwab C, et al. Angiotensin 2 mediates microvascular and hemodynamic alterations in sepsis. *J Clin Invest* 2013;123:3436-45.
28. Tuo QH, Zeng H, Stinnett A, et al. Critical role of angiotensins/Tie-2 in hyperglycemic exacerbation of myocardial infarction and impaired angiogenesis. *Am J Physiol Heart Circ Physiol* 2008;294:H2547-57.
29. Gonzalez-Quesada C, Cavalera M, Biernacka A, et al. Thrombospondin-1 induction in the diabetic myocardium stabilizes the cardiac matrix in addition to promoting vascular rarefaction through angiotensin-2 upregulation. *Circ Res* 2013;113:1331-44.
30. Saghizadeh M, Kramerov AA, Tajbakhsh J, et al. Proteinase and growth factor alterations revealed by gene microarray analysis of human diabetic corneas. *Invest Ophthalmol Vis Sci* 2005;46:3604-15.
31. Schmidt AM, Hori O, Chen JX, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. *J Clin Invest* 1995;96:1395-403.
32. Frommhold D, Kamphues A, Hepper I, et al. RAGE and ICAM-1 cooperate in mediating leukocyte recruitment during acute inflammation in vivo. *Blood* 2010;116:841-9.
33. Ziegler T, Horstkotte M, Lange P, et al. Endothelial RAGE exacerbates acute postischemic cardiac inflammation. *J Thromb Haemost* 2016;116:300-8.
34. Chibber R, Ben-Mahmud BM, Mann GE, Zhang JJ, Kohner EM. Protein kinase C  $\beta$ 2-dependent phosphorylation of core 2 GlcNAc-T promotes leukocyte-endothelial cell adhesion: a mechanism underlying capillary occlusion in diabetic retinopathy. *Diabetes* 2003;52:1519-27.

**KEY WORDS** angiogenesis, chronic myocardial ischemia, gene therapy, thymosin  $\beta$ 4

**APPENDIX** For an expanded Methods section as well as supplemental figures and a table, please see the online version of this article.